STAAR Surgical (STAA) Financials

$32.79 -0.26 (-0.79%)

Closing price 05/21/2026 04:00 PM Eastern

Extended Trading

$32.83 +0.04 (+0.13%)

As of 05/21/2026 06:42 PM Eastern

Annual Income Statements for STAAR Surgical

This table shows STAAR Surgical's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	1/1/2016	12/30/2016	12/29/2017	12/28/2018	1/3/2020	1/1/2021	12/31/2021	12/30/2022	12/29/2023	12/27/2024	1/2/2026
Net Income / (Loss) Attributable to Common Shareholders	-6.53	-12	-2.14	4.97	14	5.91	28	40	21	-20	-80
Consolidated Net Income / (Loss)	-6.53	-12	-2.14	4.97	14	5.91	28	40	21	-20	-80
Net Income / (Loss) Continuing Operations	-6.53	-12	-2.14	4.97	14	5.91	28	40	21	-20	-80
Total Pre-Tax Income	-5.61	-12	-2.30	6.64	13	8.27	31	46	34	-9.05	-82
Total Operating Income	-5.34	-13	-3.63	6.60	12	6.77	33	44	28	-13	-92
Total Gross Profit	53	58	64	92	112	118	179	223	253	240	182
Total Revenue	77	82	91	124	150	163	230	284	322	314	239
Operating Revenue	77	82	91	124	150	163	230	284	322	314	239
Total Cost of Revenue	24	24	26	32	38	45	52	61	70	74	57
Operating Cost of Revenue	24	24	26	32	38	45	52	61	70	74	57
Total Operating Expenses	58	71	68	85	100	112	145	180	225	252	274
Selling, General & Admin Expense	20	22	19	24	29	34	44	55	72	90	86
Marketing Expense	24	29	28	39	45	46	67	89	112	117	103
Research & Development Expense	15	21	20	22	25	32	34	36	40	45	40
Other Operating Expenses / (Income)	-	-	-	-	-	-	-	-	0.00	0.00	17
Restructuring Charge	-	-	-	-	-	-	-	-	0.00	0.00	29
Total Other Income / (Expense), net	-0.27	0.21	1.34	0.04	1.17	1.50	-2.04	1.75	5.60	3.56	9.45
Interest & Investment Income	0.74	0.51	0.47	0.80	1.54	0.68	0.98	3.25	7.06	6.42	4.59
Other Income / (Expense), net	-0.93	-0.30	0.87	-0.75	-0.37	0.82	-3.01	-1.50	-1.46	-2.86	4.86
Income Tax Expense	0.93	-0.32	-0.16	1.67	-1.02	2.35	3.79	5.89	12	11	-1.82
Basic Earnings per Share	($0.17)	($0.30)	($0.05)	$0.12	$0.32	$0.13	$0.58	$0.83	$0.44	($0.41)	($1.62)
Weighted Average Basic Shares Outstanding	39.26M	40.33M	41.00M	42.59M	44.49M	45.61M	47.21M	47.99M	48.52M	49.13M	49.57M
Diluted Earnings per Share	($0.17)	($0.30)	($0.05)	$0.11	$0.30	$0.12	$0.56	$0.80	$0.43	($0.41)	($1.62)
Weighted Average Diluted Shares Outstanding	39.26M	40.33M	41.00M	45.26M	46.90M	47.95M	49.46M	49.38M	49.43M	49.13M	49.57M
Weighted Average Basic & Diluted Shares Outstanding	39.26M	40.33M	42.80M	41.40M	44.96M	46.56M	47.75M	48.24M	48.87M	49.33M	49.51M

This table shows STAAR Surgical's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/29/2023	12/29/2023	3/29/2024	6/28/2024	9/27/2024	12/27/2024	3/28/2025	6/27/2025	9/26/2025	1/2/2026	4/3/2026
Net Income / (Loss) Attributable to Common Shareholders	4.82	7.76	-3.34	7.38	9.98	-34	-54	-17	8.88	-18	5.21
Consolidated Net Income / (Loss)	4.82	7.76	-3.34	7.38	9.98	-34	-54	-17	8.88	-18	5.21
Net Income / (Loss) Continuing Operations	4.82	7.76	-3.34	7.38	9.98	-34	-54	-17	8.88	-18	5.21
Total Pre-Tax Income	6.75	14	-2.21	10	13	-30	-54	-26	19	-21	8.22
Total Operating Income	6.30	10	-2.28	12	5.68	-28	-57	-30	18	-23	7.98
Total Gross Profit	64	61	61	78	68	32	28	33	78	44	69
Total Revenue	80	76	77	99	89	49	43	44	95	58	94
Operating Revenue	80	76	77	99	89	49	43	44	95	58	94
Total Cost of Revenue	17	16	16	21	20	17	15	12	17	14	25
Operating Cost of Revenue	17	16	16	21	20	17	15	12	17	14	25
Total Operating Expenses	57	50	63	67	63	60	85	63	59	67	61
Selling, General & Admin Expense	19	17	23	24	22	21	24	21	21	20	17
Marketing Expense	27	23	27	31	29	26	27	26	23	28	25
Research & Development Expense	11	11	13	12	12	12	11	10	9.21	6.92	9.93
Other Operating Expenses / (Income)	-	-	-	-	0.00	-	-	-	5.93	-	6.74
Restructuring Charge	-	-	0.00	0.00	0.00	-	23	5.25	0.03	0.69	2.68
Total Other Income / (Expense), net	0.45	3.33	0.07	-1.56	7.48	-2.42	2.92	4.05	0.30	2.19	0.24
Interest & Investment Income	1.76	1.70	2.04	1.42	1.41	1.55	1.37	1.37	0.79	1.07	0.91
Other Income / (Expense), net	-1.31	1.64	-1.97	-2.99	6.07	-3.98	1.55	2.68	-0.49	1.11	-0.67
Income Tax Expense	1.93	5.98	1.13	2.96	3.18	3.89	-0.28	-9.10	9.91	-2.34	3.01
Basic Earnings per Share	$0.10	$0.15	($0.07)	$0.15	$0.20	($0.69)	($1.10)	($0.34)	$0.18	($0.36)	$0.10
Weighted Average Basic Shares Outstanding	48.61M	48.52M	48.91M	49.13M	49.20M	49.13M	49.34M	49.52M	49.63M	49.57M	49.91M
Diluted Earnings per Share	$0.10	$0.16	($0.07)	$0.15	$0.20	($0.69)	($1.10)	($0.34)	$0.18	($0.36)	$0.10
Weighted Average Diluted Shares Outstanding	49.37M	49.43M	48.91M	49.81M	49.73M	49.13M	49.34M	49.52M	50.55M	49.57M	50.90M

This table details how cash moves in and out of STAAR Surgical's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	1/1/2016	12/30/2016	12/29/2017	12/28/2018	1/3/2020	1/1/2021	12/31/2021	12/30/2022	12/29/2023	12/27/2024	1/2/2026
Net Change in Cash & Equivalents	0.39	0.60	4.52	85	16	32	47	-113	97	-39	8.99
Net Cash From Operating Activities	-2.16	1.05	2.85	13	26	21	44	36	15	16	-34
Net Cash From Continuing Operating Activities	-2.16	1.05	2.85	13	26	21	44	36	15	16	-34
Net Income / (Loss) Continuing Operations	-6.53	-12	-2.14	4.97	14	5.91	28	40	21	-20	-80
Consolidated Net Income / (Loss)	-6.53	-12	-2.14	4.97	14	5.91	28	40	21	-20	-80
Depreciation Expense	2.20	2.66	3.13	2.43	3.67	3.06	3.61	4.48	5.11	6.89	8.32
Amortization Expense	0.21	0.23	0.22	0.03	0.03	0.04	0.03	0.03	0.01	0.00	0.41
Non-Cash Adjustments To Reconcile Net Income	6.30	9.74	5.92	8.55	11	11	16	20	27	19	40
Changes in Operating Assets and Liabilities, net	-4.33	0.54	-4.28	-3.22	-3.06	0.80	-3.06	-28	-38	9.96	-2.37
Net Cash From Investing Activities	-2.04	-3.21	-1.05	-2.25	-10	-8.40	-14	-156	74	-59	46
Net Cash From Continuing Investing Activities	-2.04	-3.21	-1.05	-2.25	-10	-8.40	-14	-156	74	-59	46
Purchase of Property, Plant & Equipment	-2.05	-3.21	-1.05	-2.25	-10	-8.40	-14	-18	-18	-23	-5.82
Purchase of Investments	-	-	-	-	-	0.00	0.00	-156	-52	-80	-75
Sale and/or Maturity of Investments	-	-	-	-	-	0.00	0.00	17	145	44	128
Net Cash From Financing Activities	4.58	2.95	2.44	75	0.15	20	18	8.30	7.42	5.72	-4.56
Net Cash From Continuing Financing Activities	4.58	2.95	2.44	75	0.15	20	18	8.30	7.42	5.72	-4.56
Repayment of Debt	-0.39	-0.42	-1.30	-2.65	-3.31	-1.08	-1.65	-0.13	-0.16	-0.17	-0.04
Repurchase of Common Equity	-	-	-	-	-	-	-	-	0.00	0.00	-6.46
Other Financing Activities, net	4.97	3.38	3.74	5.14	3.46	21	19	8.42	7.58	5.89	1.95
Effect of Exchange Rate Changes	0.02	-0.20	0.28	0.20	0.20	0.37	-0.86	-0.86	0.20	-1.11	1.44

This table details how cash moves in and out of STAAR Surgical's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/29/2023	12/29/2023	3/29/2024	6/28/2024	9/27/2024	12/27/2024	3/28/2025	6/27/2025	9/26/2025	1/2/2026	4/3/2026
Net Change in Cash & Equivalents	33	56	41	-31	-29	-20	29	-5.98	9.02	-23	-21
Net Cash From Operating Activities	-5.98	32	22	-10	3.82	0.64	-5.73	-27	2.67	-3.91	-22
Net Cash From Continuing Operating Activities	-5.98	32	22	-10	3.82	0.64	-5.73	-27	2.67	-3.91	-22
Net Income / (Loss) Continuing Operations	4.82	7.76	-3.34	7.38	9.98	-34	-54	-17	8.88	-18	5.21
Consolidated Net Income / (Loss)	4.82	7.76	-3.34	7.38	9.98	-34	-54	-17	8.88	-18	5.21
Depreciation Expense	1.35	1.37	1.24	1.52	1.76	2.38	2.34	1.98	2.00	2.01	2.11
Amortization Expense	-0.00	-0.16	0.00	-	-	-	0.05	-	-	0.41	0.10
Non-Cash Adjustments To Reconcile Net Income	8.98	-0.29	1.51	8.63	5.24	0.14	19	6.14	9.17	6.13	7.42
Changes in Operating Assets and Liabilities, net	-21	23	22	-28	-13	32	27	-19	-17	5.85	-37
Net Cash From Investing Activities	32	22	16	-21	-35	-19	35	25	5.28	-19	2.15
Net Cash From Continuing Investing Activities	32	22	16	-21	-35	-19	35	25	5.28	-19	2.15
Purchase of Property, Plant & Equipment	-9.19	-3.09	-5.20	-6.24	-6.23	-5.73	-1.47	-1.79	-0.88	-1.68	-0.44
Purchase of Investments	-9.71	0.00	0.00	-20	-41	-19	-15	-	-12	-49	-4.52
Sale and/or Maturity of Investments	51	25	21	5.82	12	5.28	52	27	18	31	7.11
Net Cash From Financing Activities	7.11	0.37	4.06	0.16	1.62	-0.11	-0.95	-4.54	0.98	-0.05	-1.69
Net Cash From Continuing Financing Activities	7.11	0.37	4.06	0.16	1.62	-0.11	-0.95	-4.54	0.98	-0.05	-1.69
Repayment of Debt	-0.04	-0.04	-0.04	-0.04	-0.04	-0.04	-0.04	-	-	-	0.00
Other Financing Activities, net	7.15	0.41	4.10	0.21	1.66	-0.07	-0.91	-0.06	2.97	-0.05	-1.69
Effect of Exchange Rate Changes	-0.24	0.87	-0.94	-0.33	1.04	-0.88	0.29	0.69	0.09	0.37	-0.05

This table presents STAAR Surgical's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	1/1/2016	12/30/2016	12/29/2017	12/28/2018	1/3/2020	1/1/2021	12/31/2021	12/30/2022	12/29/2023	12/27/2024	1/2/2026
Total Assets	63	65	68	167	208	257	346	419	489	510	452
Total Current Assets	49	50	54	152	175	216	271	312	365	368	312
Cash & Equivalents	13	14	19	104	120	152	200	86	183	144	153
Short-Term Investments	-	-	-	-	-	-	0.00	125	38	86	34
Accounts Receivable	16	16	18	26	31	35	44	62	95	78	50
Inventories, net	16	15	13	17	17	18	17	24	35	43	55
Prepaid Expenses	3.64	4.35	4.21	5.05	6.56	11	11	13	15	16	18
Plant, Property, & Equipment, net	10	12	9.78	11	17	24	36	51	67	85	73
Total Noncurrent Assets	3.79	4.17	4.27	4.32	16	17	38	56	57	57	67
Goodwill	1.79	1.79	1.79	1.79	1.79	1.79	1.79	1.79	1.79	1.79	1.79
Noncurrent Deferred & Refundable Income Taxes	0.72	1.14	1.24	1.28	4.41	4.94	3.81	8.74	5.19	0.79	3.37
Other Noncurrent Operating Assets	0.62	0.77	0.97	1.01	7.44	9.37	32	31	38	54	62
Total Liabilities & Shareholders' Equity	63	65	68	167	208	257	346	419	489	510	452
Total Liabilities	24	28	25	35	48	60	87	83	103	112	107
Total Current Liabilities	18	21	19	28	34	41	49	52	65	70	69
Accounts Payable	6.69	8.31	6.03	6.52	8.05	7.47	8.70	12	14	17	12
Other Current Liabilities	6.31	7.28	7.34	17	25	32	40	40	51	54	57
Total Noncurrent Liabilities	6.22	6.51	5.91	7.19	13	19	38	31	38	42	39
Asset Retirement Reserve & Litigation Obligation	0.16	0.20	0.20	0.21	0.21	0.22	0.20	0.22	0.10	0.04	0.05
Noncurrent Deferred Revenue	0.09	0.06	0.17	0.19	-	-	-	-	-	0.00	0.09
Noncurrent Employee Benefit Liabilities	3.89	4.00	4.65	5.31	7.84	12	8.76	1.94	5.06	6.74	6.38
Other Noncurrent Operating Liabilities	-	-	-	0.00	4.09	6.54	28	27	31	35	32
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	39	38	43	132	160	197	259	336	386	397	344
Total Preferred & Common Equity	39	38	43	132	160	197	259	336	386	397	344
Total Common Equity	39	38	43	132	160	197	259	336	386	397	344
Common Stock	187	198	205	290	305	339	374	405	437	472	505
Retained Earnings	-147	-159	-161	-156	-142	-136	-111	-69	-47	-68	-148
Treasury Stock	-	-	-	-	-	-	-	-	-	0.00	-6.46
Accumulated Other Comprehensive Income / (Loss)	-1.58	-1.05	-1.15	-1.32	-3.05	-5.55	-4.05	0.16	-4.11	-7.03	-6.51

This table presents STAAR Surgical's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q2 2022	Q3 2022	Q1 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	7/1/2022	9/30/2022	6/30/2023	9/29/2023	3/29/2024	6/28/2024	9/27/2024	3/28/2025	6/27/2025	9/26/2025	4/3/2026
Total Assets	376	395	441	472	493	513	538	457	438	456	451
Total Current Assets	296	297	328	347	366	384	397	326	293	321	312
Cash & Equivalents	202	129	95	127	224	193	164	173	167	176	132
Short-Term Investments	-	82	97	61	21	42	72	50	23	17	32
Accounts Receivable	63	55	94	112	65	94	105	40	34	60	81
Inventories, net	18	20	25	31	39	39	40	48	53	53	50
Prepaid Expenses	13	10	16	16	17	16	16	16	15	15	18
Plant, Property, & Equipment, net	43	48	56	63	72	78	82	75	74	73	72
Total Noncurrent Assets	37	50	57	62	54	51	59	56	71	63	67
Goodwill	1.79	1.79	1.79	1.79	1.79	1.79	1.79	1.79	1.79	1.79	1.79
Intangible Assets	0.18	0.17	0.00	0.00	-	-	-	-	-	-	34
Noncurrent Deferred & Refundable Income Taxes	3.22	3.71	4.67	8.56	5.13	5.08	5.32	4.00	12	1.98	1.09
Other Noncurrent Operating Assets	31	30	32	37	40	44	52	50	57	59	30
Total Liabilities & Shareholders' Equity	376	395	441	472	493	513	538	457	438	456	451
Total Liabilities	77	75	87	93	100	104	109	107	101	103	99
Total Current Liabilities	47	45	54	57	63	66	66	68	59	62	61
Accounts Payable	13	7.57	11	8.79	17	19	15	11	12	9.18	8.70
Other Current Liabilities	34	38	43	48	46	47	52	57	47	52	52
Total Noncurrent Liabilities	30	29	33	36	37	37	43	39	42	41	38
Asset Retirement Reserve & Litigation Obligation	0.17	0.16	0.10	0.10	0.10	0.11	0.13	0.04	0.05	0.04	0.04
Noncurrent Deferred Revenue	-	-	-	-	-	-	-	-	-	0.09	0.09
Noncurrent Employee Benefit Liabilities	1.82	1.23	3.05	3.03	4.78	4.81	6.56	5.88	6.52	7.01	6.44
Other Noncurrent Operating Liabilities	27	26	28	32	31	31	35	33	35	34	31
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	299	320	354	379	393	409	428	350	337	354	352
Total Preferred & Common Equity	299	320	354	379	393	409	428	350	337	354	352
Total Common Equity	299	320	354	379	393	409	428	350	337	354	352
Common Stock	388	399	420	437	448	458	467	477	485	496	508
Retained Earnings	-89	-78	-64	-55	-51	-43	-33	-122	-139	-130	-143
Treasury Stock	-	-	-	-	-	-	-	-	-4.48	-6.46	-6.46
Accumulated Other Comprehensive Income / (Loss)	0.25	-0.31	-2.52	-2.89	-4.71	-5.46	-5.60	-5.60	-5.65	-6.53	-6.78

This table displays calculated financial ratios and metrics derived from STAAR Surgical's official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	1/1/2016	12/30/2016	12/29/2017	12/28/2018	1/3/2020	1/1/2021	12/31/2021	12/30/2022	12/29/2023	12/27/2024	1/2/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	-	49,741,953.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	49,741,953.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-1.62
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Net Operating Profit after Tax (NOPAT)	-3.74	-8.86	-2.54	4.94	13	4.84	29	38	18	-8.83	-64
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	11.34%	4.61%	-2.22%	-18.65%
Earnings before Interest and Taxes (EBIT)	-6.27	-13	-2.77	5.84	11	7.59	30	42	27	-15	-87
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-3.87	-10	0.59	8.31	15	11	34	47	32	-8.58	-78
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-4.80	-9.42	-2.48	2.81	3.46	0.76	16	-13	-25	-22	-54
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	30	31	31	33	42	46	59	111	154	167	157
Increase / (Decrease) in Invested Capital	1.07	0.56	-0.06	2.13	9.32	4.08	13	52	43	13	-10
Book Value per Share	$0.97	$0.93	$1.04	$3.00	$3.58	$4.28	$5.43	$6.97	$7.91	$8.06	$6.92
Tangible Book Value per Share	$0.91	$0.88	$0.99	$2.95	$3.54	$4.23	$5.39	$6.93	$7.87	$8.03	$6.88
Total Capital	44	45	49	137	162	199	259	336	386	397	344
Total Debt	4.73	6.82	6.25	4.24	2.19	1.42	0.38	0.21	0.04	0.00	0.00
Total Long-Term Debt	0.20	1.34	0.53	0.46	0.37	0.04	0.38	0.21	0.04	0.00	0.00
Net Debt	-8.68	-7.18	-12	-100	-118	-151	-199	-225	-232	-230	-188
Capital Expenditures (CapEx)	2.04	3.21	1.05	2.25	10	8.40	14	18	18	23	5.82
Debt-free, Cash-free Net Working Capital (DFCFNWC)	22	20	22	24	22	24	23	48	80	67	56
Debt-free Net Working Capital (DFNWC)	36	34	41	128	142	177	223	260	300	298	243
Net Working Capital (NWC)	31	28	35	124	140	175	223	260	300	298	243
Net Nonoperating Expense (NNE)	2.80	3.27	-0.40	-0.03	-1.27	-1.07	1.79	-1.52	-3.55	11	16
Net Nonoperating Obligations (NNO)	-8.68	-7.18	-12	-100	-118	-151	-199	-225	-232	-230	-188
Total Depreciation and Amortization (D&A)	2.40	2.89	3.35	2.46	3.70	3.10	3.64	4.51	5.12	6.89	8.73
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.17)	($0.30)	($0.05)	$0.12	$0.32	$0.13	$0.52	$0.81	$0.44	($0.41)	($1.62)
Adjusted Weighted Average Basic Shares Outstanding	39.26M	40.75M	41.42M	42.59M	44.49M	45.61M	47.21M	47.99M	48.52M	49.13M	49.57M
Adjusted Diluted Earnings per Share	($0.17)	($0.30)	($0.05)	$0.11	$0.30	$0.12	$0.50	$0.78	$0.43	($0.41)	($1.62)
Adjusted Weighted Average Diluted Shares Outstanding	39.26M	40.75M	41.42M	45.26M	46.90M	47.95M	49.46M	49.38M	49.43M	49.13M	49.57M
Adjusted Basic & Diluted Earnings per Share	$0.00	($0.30)	($0.05)	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	40.16M	40.33M	41.00M	44.21M	44.96M	46.56M	47.75M	48.24M	48.87M	49.33M	49.51M
Normalized Net Operating Profit after Tax (NOPAT)	-3.74	-8.86	-2.54	4.94	8.30	4.84	29	38	18	-8.83	-44
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-

This table displays calculated financial ratios and metrics derived from STAAR Surgical's official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/29/2023	12/29/2023	3/29/2024	6/28/2024	9/27/2024	12/27/2024	3/28/2025	6/27/2025	9/26/2025	1/2/2026	4/3/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	49,741,953.00	49,512,749.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	49,741,953.00	49,512,749.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-0.37	0.11
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	5.60%	19.09%	5.21%	7.26%	10.31%	-35.82%	-44.94%	-55.23%	6.93%	-	119.59%
EBITDA Growth	-50.15%	137.75%	-174.96%	27.77%	113.58%	-322.70%	-1,677.32%	-342.53%	48.05%	-	117.81%
EBIT Growth	-57.06%	187.49%	-246.63%	32.68%	135.89%	-364.84%	-1,214.78%	-406.12%	53.17%	-	113.09%
NOPAT Growth	-59.80%	438.69%	-199.30%	38.39%	-4.13%	-432.61%	-2,416.48%	-346.89%	102.87%	-	112.58%
Net Income Growth	-53.06%	14.68%	-223.21%	21.69%	107.18%	-541.31%	-1,523.57%	-327.84%	-10.98%	-	109.60%
EPS Growth	-52.38%	14.29%	-240.00%	25.00%	100.00%	-531.25%	-1,471.43%	-326.67%	-10.00%	-	109.09%
Operating Cash Flow Growth	-124.78%	976.40%	525.60%	-65.13%	163.87%	-97.99%	-126.45%	-161.68%	-30.11%	-	-278.36%
Free Cash Flow Firm Growth	-152.95%	26.84%	103.41%	-259.94%	85.78%	11.11%	-1,424.33%	103.62%	464.49%	-	-110.41%
Invested Capital Growth	84.91%	38.62%	-2.50%	0.00%	8.60%	8.64%	-9.57%	-15.52%	-16.16%	-	48.16%
Revenue Q/Q Growth	-13.00%	-5.02%	1.42%	27.99%	-10.52%	-44.75%	-12.99%	4.06%	113.75%	-	61.80%
EBITDA Q/Q Growth	-22.54%	109.52%	-122.72%	446.53%	29.47%	-318.46%	-81.33%	52.71%	179.03%	-	149.32%
EBIT Q/Q Growth	-25.83%	141.67%	-135.28%	309.79%	31.87%	-371.33%	-75.16%	51.15%	165.98%	-	133.65%
NOPAT Q/Q Growth	-26.78%	30.68%	-127.18%	632.08%	-49.28%	-553.37%	-105.66%	47.80%	141.68%	-	131.62%
Net Income Q/Q Growth	-20.56%	61.01%	-143.05%	320.99%	35.25%	-442.97%	-58.38%	68.99%	152.84%	-	128.43%
EPS Q/Q Growth	-16.67%	60.00%	-143.75%	314.29%	33.33%	-445.00%	-59.42%	69.09%	152.94%	-	127.78%
Operating Cash Flow Q/Q Growth	5.25%	635.05%	-32.18%	-148.03%	136.65%	-83.18%	-993.15%	-375.22%	109.79%	-	-454.29%
Free Cash Flow Firm Q/Q Growth	-174.34%	51.91%	105.47%	-8,286.30%	93.39%	-200.59%	18.58%	122.36%	566.08%	-	-870.23%
Invested Capital Q/Q Growth	0.00%	-13.21%	-8.39%	23.43%	10.67%	-13.18%	-23.75%	15.31%	9.84%	-	20.32%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	79.24%	79.62%	78.90%	79.20%	77.31%	64.65%	65.76%	74.01%	82.21%	-	73.63%
EBITDA Margin	7.88%	17.37%	-3.89%	10.54%	15.25%	-60.29%	-125.65%	-57.10%	21.11%	-	10.18%
Operating Margin	7.84%	13.64%	-2.95%	12.02%	6.41%	-57.02%	-134.78%	-67.61%	19.52%	-	8.53%
EBIT Margin	6.20%	15.79%	-5.49%	9.00%	13.27%	-65.14%	-131.14%	-61.55%	19.00%	-	7.82%
Profit (Net Income) Margin	6.00%	10.17%	-4.32%	7.45%	11.27%	-69.92%	-127.29%	-37.93%	9.38%	-	5.57%
Tax Burden Percent	71.41%	56.45%	151.02%	71.41%	75.84%	112.84%	99.50%	64.87%	47.28%	-	63.35%
Interest Burden Percent	135.41%	114.11%	52.05%	115.96%	111.97%	95.13%	97.55%	94.99%	104.39%	-	112.41%
Effective Tax Rate	28.59%	43.55%	0.00%	28.59%	24.16%	0.00%	0.00%	0.00%	52.72%	-	36.65%
Return on Invested Capital (ROIC)	12.74%	18.79%	-4.73%	32.91%	8.99%	-78.20%	-196.61%	-66.32%	12.05%	-	9.94%
ROIC Less NNEP Spread (ROIC-NNEP)	12.59%	17.96%	-3.97%	33.86%	6.40%	-71.86%	-190.70%	-68.28%	11.98%	-	9.86%
Return on Net Nonoperating Assets (RNNOA)	-7.67%	-11.39%	2.46%	-19.49%	-3.47%	42.46%	121.92%	38.95%	-6.57%	-	-5.43%
Return on Equity (ROE)	5.06%	7.40%	-2.27%	13.42%	5.52%	-35.74%	-74.69%	-27.37%	5.48%	-	4.51%
Cash Return on Invested Capital (CROIC)	-48.86%	-18.90%	11.77%	-182.40%	0.41%	-13.80%	-25.34%	-31.07%	-20.78%	-	-50.49%
Operating Return on Assets (OROA)	4.44%	11.22%	-3.84%	5.85%	8.97%	-40.97%	-77.07%	-29.07%	8.82%	-	5.00%
Return on Assets (ROA)	4.30%	7.23%	-3.02%	4.84%	7.62%	-43.98%	-74.81%	-17.91%	4.35%	-	3.56%
Return on Common Equity (ROCE)	5.06%	7.40%	-2.27%	13.42%	5.52%	-35.74%	-74.69%	-27.37%	5.48%	-	4.51%
Return on Equity Simple (ROE_SIMPLE)	5.38%	0.00%	3.89%	4.06%	5.09%	0.00%	-20.31%	0.00%	0.00%	-	0.00%
Net Operating Profit after Tax (NOPAT)	4.49	5.87	-1.60	8.50	4.31	-20	-40	-21	8.74	-16	5.05
NOPAT Margin	5.60%	7.70%	-2.06%	8.58%	4.86%	-39.91%	-94.35%	-47.33%	9.23%	-	5.40%
Net Nonoperating Expense Percent (NNEP)	0.15%	0.82%	-0.76%	-0.95%	2.59%	-6.35%	-5.91%	1.96%	0.07%	-	0.08%
Return On Investment Capital (ROIC_SIMPLE)	-	1.52%	-	-	-	-4.92%	-11.48%	-6.23%	2.47%	-4.64%	1.43%
Cost of Revenue to Revenue	20.76%	20.38%	21.10%	20.80%	22.69%	35.35%	34.24%	26.00%	17.79%	-	26.37%
SG&A Expenses to Revenue	23.99%	22.10%	30.03%	23.88%	24.48%	43.60%	57.43%	47.31%	21.92%	-	18.20%
R&D to Revenue	14.28%	14.25%	17.30%	14.20%	16.36%	24.60%	32.08%	23.16%	9.72%	-	10.61%
Operating Expenses to Revenue	71.40%	65.97%	81.85%	67.18%	70.89%	121.67%	200.54%	141.61%	62.69%	-	65.10%
Earnings before Interest and Taxes (EBIT)	4.98	12	-4.25	8.91	12	-32	-56	-27	18	-22	7.31
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	6.33	13	-3.01	10	14	-30	-54	-25	20	-19	9.52
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	5.15	3.95	4.76	5.72	4.28	3.00	2.51	2.49	3.75	-	2.84
Price to Tangible Book Value (P/TBV)	5.17	3.97	4.78	5.74	4.30	3.02	2.52	2.50	3.77	-	3.16
Price to Revenue (P/Rev)	6.28	4.73	5.73	7.03	5.37	3.80	3.14	3.73	5.76	-	3.45
Price to Earnings (P/E)	95.74	71.37	122.16	140.80	84.10	0.00	0.00	0.00	0.00	-	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Earnings Yield	1.04%	1.40%	0.82%	0.71%	1.19%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Enterprise Value to Invested Capital (EV/IC)	9.87	8.41	11.49	12.12	8.30	5.77	5.15	4.42	7.05	-	4.44
Enterprise Value to Revenue (EV/Rev)	5.63	4.00	4.96	6.32	4.68	3.07	2.35	2.89	4.92	-	2.88
Enterprise Value to EBITDA (EV/EBITDA)	72.55	40.66	65.37	77.91	46.67	0.00	0.00	0.00	0.00	-	0.00
Enterprise Value to EBIT (EV/EBIT)	93.01	48.48	82.94	97.01	56.06	0.00	0.00	0.00	0.00	-	0.00
Enterprise Value to NOPAT (EV/NOPAT)	119.33	72.54	122.89	137.65	99.82	0.00	0.00	0.00	0.00	-	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	88.48	39.08	56.46	33.91	61.21	0.00	0.00	0.00	-	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	96.41	0.00	2,105.46	0.00	0.00	0.00	0.00	-	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Financial Leverage	-0.61	-0.63	-0.62	-0.58	-0.54	-0.59	-0.64	-0.57	-0.55	-	-0.55
Leverage Ratio	1.24	1.26	1.25	1.25	1.25	1.27	1.28	1.27	1.27	-	1.29
Compound Leverage Factor	1.68	1.43	0.65	1.45	1.40	1.21	1.25	1.21	1.33	-	1.45
Debt to Total Capital	0.02%	0.01%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Long-Term Debt to Total Capital	0.02%	0.01%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Common Equity to Total Capital	99.98%	99.99%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	-	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Net Debt to EBITDA	-8.37	-7.32	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Debt to NOPAT	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Net Debt to NOPAT	-13.77	-13.06	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Long-Term Debt to NOPAT	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Altman Z-Score	13.85	10.24	12.47	14.87	11.40	7.31	5.41	5.47	8.69	-	7.00
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	6.11	5.62	5.84	5.80	5.99	5.23	4.78	4.94	5.21	-	5.12
Quick Ratio	5.29	4.85	4.94	4.97	5.13	4.39	3.84	3.79	4.10	-	4.02
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-77	-37	2.02	-165	-11	-33	-27	5.97	40	-5.79	-56
Operating Cash Flow to CapEx	-65.05%	1,035.27%	416.76%	-166.98%	61.24%	11.21%	-390.60%	-1,520.59%	302.04%	-	-4,897.29%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.72	0.71	0.70	0.65	0.68	0.63	0.59	0.47	0.46	-	0.64
Accounts Receivable Turnover	3.70	4.10	4.10	3.55	3.15	3.64	5.34	3.50	2.80	-	4.79
Inventory Turnover	2.69	2.35	2.19	1.76	2.03	1.90	1.67	1.37	1.29	-	1.37
Fixed Asset Turnover	5.59	5.48	5.09	4.30	4.72	4.14	3.79	2.95	2.99	-	3.96
Accounts Payable Turnover	8.37	5.55	5.01	3.63	6.18	4.91	5.18	4.04	5.05	-	6.66
Days Sales Outstanding (DSO)	98.72	88.95	88.97	102.83	115.99	100.35	68.36	104.27	130.28	-	76.12
Days Inventory Outstanding (DIO)	135.90	155.10	166.74	207.40	179.63	192.61	218.06	265.49	283.64	-	266.34
Days Payable Outstanding (DPO)	43.58	65.75	72.88	100.63	59.05	74.31	70.47	90.24	72.30	-	54.83
Cash Conversion Cycle (CCC)	191.04	178.31	182.83	209.60	236.57	218.65	215.95	279.52	341.63	-	287.63
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	177	154	141	174	192	167	127	147	161	157	188
Invested Capital Turnover	2.28	2.44	2.29	3.83	1.85	1.96	2.08	1.40	1.31	-	1.84
Increase / (Decrease) in Invested Capital	81	43	-3.61	174	15	13	-13	-27	-31	-10	61
Enterprise Value (EV)	1,747	1,291	1,617	2,104	1,595	962	655	648	1,135	-	837
Market Capitalization	1,949	1,524	1,869	2,339	1,831	1,193	877	838	1,328	-	1,001
Book Value per Share	$7.81	$7.91	$8.03	$8.33	$8.70	$8.06	$7.10	$6.80	$7.14	$6.92	$7.12
Tangible Book Value per Share	$7.77	$7.87	$7.99	$8.29	$8.67	$8.03	$7.06	$6.76	$7.10	$6.88	$6.39
Total Capital	379	386	393	409	428	397	350	337	354	344	352
Total Debt	0.08	0.04	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.08	0.04	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-202	-232	-252	-235	-236	-230	-223	-190	-193	-188	-164
Capital Expenditures (CapEx)	9.19	3.09	5.20	6.24	6.23	5.73	1.47	1.79	0.88	1.68	0.44
Debt-free, Cash-free Net Working Capital (DFCFNWC)	102	80	58	82	95	67	35	44	67	56	88
Debt-free Net Working Capital (DFNWC)	290	300	303	318	331	298	258	234	260	243	251
Net Working Capital (NWC)	290	300	303	318	331	298	258	234	260	243	251
Net Nonoperating Expense (NNE)	-0.32	-1.88	1.74	1.12	-5.67	15	14	-4.16	-0.14	2.32	-0.15
Net Nonoperating Obligations (NNO)	-202	-232	-252	-235	-236	-230	-223	-190	-193	-188	-164
Total Depreciation and Amortization (D&A)	1.34	1.21	1.24	1.52	1.76	2.38	2.34	1.98	2.00	2.42	2.21
Debt-free, Cash-free Net Working Capital to Revenue	32.94%	24.66%	17.75%	24.76%	27.78%	21.39%	12.68%	19.46%	29.02%	-	30.14%
Debt-free Net Working Capital to Revenue	93.59%	93.12%	92.89%	95.41%	96.93%	94.82%	92.48%	104.06%	112.57%	-	86.58%
Net Working Capital to Revenue	93.59%	93.12%	92.89%	95.41%	96.93%	94.82%	92.48%	104.06%	112.57%	-	86.58%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.10	$0.15	($0.07)	$0.15	$0.20	($0.69)	($1.10)	($0.34)	$0.18	($0.36)	$0.10
Adjusted Weighted Average Basic Shares Outstanding	48.61M	48.52M	48.91M	49.13M	49.20M	49.13M	49.34M	49.52M	49.63M	49.57M	49.91M
Adjusted Diluted Earnings per Share	$0.10	$0.16	($0.07)	$0.15	$0.20	($0.69)	($1.10)	($0.34)	$0.18	($0.36)	$0.10
Adjusted Weighted Average Diluted Shares Outstanding	49.37M	49.43M	48.91M	49.81M	49.73M	49.13M	49.34M	49.52M	50.55M	49.57M	50.90M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	48.82M	48.87M	49.13M	49.19M	49.28M	49.33M	49.53M	49.55M	49.74M	49.51M	0.00
Normalized Net Operating Profit after Tax (NOPAT)	4.49	5.87	-1.60	8.50	4.31	-20	-24	-17	13	-16	6.75
Normalized NOPAT Margin	5.60%	7.70%	-2.06%	8.58%	4.86%	-39.91%	-57.09%	-39.04%	13.68%	-	7.22%
Pre Tax Income Margin	8.40%	18.01%	-2.86%	10.44%	14.85%	-61.97%	-127.93%	-58.47%	19.83%	-	8.79%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%

Financials Breakdown Chart

Key Financial Trends

STAAR Surgical (STAA) has shown a mix of strong profitability in a single standout quarter in 2025, alongside ongoing cash generation and a solid balance sheet. Below are the most notable trends pulled from the last four years of quarterly statements provided.

Q3 2025 standout metrics: revenue about $94.7M, gross margin roughly 82%, and net income around $8.9M (EPS ~$0.18).
Healthy balance sheet and liquidity: cash and equivalents around $176M, total assets about $456M, and total equity around $354M with modest liabilities (~$103M).
Operating cash flow improvement: Q3 2025 produced positive net cash from continuing operating activities (about $2.7M), signaling a clearer path to cash generation from core operations.
Cash flow composition in Q3 2025 includes investing inflows: net continuing investing activities about $5.28M (notably from investing activities), plus a modest financing inflow, contributing to a total quarterly cash rise of roughly $9.02M; also a small share repurchase (~$2.0M) occurred.
Gross margin trend improving through 2025: gross margins rose from the mid-60s% earlier in the year to about 82% in Q3 2025, then remained strong (~75-76%) in Q4 2025, indicating improving product economics or mix.
Revenue volatility: 2025 shows a sharp quarter-to-quarter swing (e.g., a big jump in Q3 2025 to ~$94.7M followed by a drop to ~ $57.8M in Q4 2025), suggesting seasonality or one-off factors rather than an extended, steady growth trend.
Profitability not yet consistent across quarters: 2025 results include a mix of losses and a single quarterly profit (Q3 2025), with Q1 and Q4 2025 reporting net losses, underscoring earnings volatility.
Operating expense pressure: SG&A, marketing, and R&D remain sizable relative to revenue in several quarters, contributing to operating losses in most periods (e.g., large negative operating income in multiple quarters).
Cash-flow from operations uneven: several quarters show negative cash from operating activities (e.g., Q1 2025 and Q2 2025), raising near-term liquidity considerations despite a strong cash balance overall.
Accounts receivable concentration risk: accounts receivable around the $60M level in many periods (notably Q3 2025), which can imply slower cash conversion and working-capital sensitivity if collections deteriorate.

05/22/26 01:28 AM ETAI Generated. May Contain Errors.

STAAR Surgical Financials - Frequently Asked Questions

According to the most recent income statement we have on file, STAAR Surgical's financial year ends in January. Their financial year 2026 ended on January 2, 2026.

STAAR Surgical's net income appears to be on an upward trend, with a most recent value of -$80.45 million in 2025, rising from -$6.53 million in 2015. The previous period was -$20.21 million in 2024. Find out what analysts predict for STAAR Surgical in the coming months.

STAAR Surgical's total operating income in 2025 was -$91.71 million, based on the following breakdown:

Total Gross Profit: $182.42 million
Total Operating Expenses: $274.13 million

Over the last 10 years, STAAR Surgical's total revenue changed from $77.12 million in 2015 to $239.44 million in 2025, a change of 210.5%.

STAAR Surgical's total liabilities were at $107.49 million at the end of 2025, a 4.2% decrease from 2024, and a 345.9% increase since 2015.

In the past 10 years, STAAR Surgical's cash and equivalents has ranged from $13.40 million in 2015 to $199.71 million in 2021, and is currently $153.15 million as of their latest financial filing in 2025.

Over the last 10 years, STAAR Surgical's book value per share changed from 0.97 in 2015 to 6.92 in 2025, a change of 610.5%.

Related Companies

Financial statements for NASDAQ:STAA last updated on 5/17/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

STAAR Surgical (STAA) Financials

Financials Breakdown Chart

Key Financial Trends

STAAR Surgical Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

STAAR Surgical (STAA) Financials

Annual Income Statements for STAAR Surgical

Quarterly Income Statements for STAAR Surgical

Annual Cash Flow Statements for STAAR Surgical

Quarterly Cash Flow Statements for STAAR Surgical

Annual Balance Sheets for STAAR Surgical

Quarterly Balance Sheets for STAAR Surgical

Annual Metrics And Ratios for STAAR Surgical

Quarterly Metrics And Ratios for STAAR Surgical

Financials Breakdown Chart

Key Financial Trends

STAAR Surgical Financials - Frequently Asked Questions

When does STAAR Surgical's fiscal year end?

How has STAAR Surgical's net income changed over the last 10 years?

What is STAAR Surgical's operating income?

How has STAAR Surgical's revenue changed over the last 10 years?

How much debt does STAAR Surgical have?

How much cash does STAAR Surgical have?

How has STAAR Surgical's book value per share changed over the last 10 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools